Barrett L, Mellor R, Ritter A, McLauchlan L, Kearnes M. Navigating the grey: experiences of incremental cannabis reform in Australia. Drug Alcohol Rev. 2022 Nov;41(7):1621-9. doi: 10.1111/dar.13518
Mellor R, Lancaster K, Ritter A. Examining untreated and treated alcohol problem resolution in an Australian online survey sample. Drug Alcohol Rev. 2021 Sep;40(6):1037-46. doi: 10.1111/dar.13257
Ensor CR, Iasella CJ, Harrigan (Zhang) KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018 Jun;18(6):1527-33. doi: 10.1111/ajt.14723
Khellaf M, Le Moine JG, Poitrinal P, Francesconi C, Haddad A, Bierling P, Michel M, Eckert L, Launois R, Godeau B. Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis. Ann Hematol. 2011 Apr;90(4):441-6. doi: 10.1007/s00277-010-1087-x
Rivero E, Varas-Lorenzo C, Maguire AR, Eisen HJ, Pedersen TR, Nashan B, Elkammas E. 10-Year predicted probability of coronary heart disease in renal transplant recipients treated with everolimus or mmf. Poster presented at the American Transplant Congress; April 2002. Washington, DC. [abstract] Am J Transplant. 2002; 2(Suppl 3):418.